Eleanor N. Dana Cancer Center

/centers/cancer/
/centers/cancer/

Services

/  

Contact Us

Clinical trials at the Eleanor N. Dana Cancer Center

Consult your medical team to find out whether you are a candidate for one of our clinical trials. Since we are constantly expanding the list of clinical trials we offer, if you don't see your cancer indication listed below please contact the Eleanor N. Dana Cancer Center at 419.383.6644. You can learn more about clinical trials here.


All Cancer Indications

Molecular Target Registry

+ More Info


Breast Cancer

Phase I study of KN026 in HER2 cancer

Mechanism:  Anti-HER2 bispecific antibody to non overlapping HER2 epitopes

+ More Info


Colon Cancer

Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Advanced Solid Tumors

Mechanism:  Combination of non marrow suppressive signal pathway inhibition of PI3K with immune enhancing activity of checkpoint inhibitors to generate anticancer activity

+ More Info


Glioblastoma

Phase II of OKN-007 and TMZ in Recurrent Glioblastoma

Mechanism:  small molecule that targets heparin sulfate proteoglycans (HSPGs), can increase glioma tumor cell apoptosis and decrease proliferation and angiogenesis. It also increases vascular permeability, allowing drugs like temozolomide (TMZ) to accumulate in brain tissue.

+ More Info


Lung Cancer

Phase 1 Study of NBF-006 in Advanced Solid Tumor

Mechanism:  siRNA targeting Glutathione S-transferase P (GSTP) which modulates ras signaling.  Control of GSTP will inhibit ras signaling as related to cancer growth.  Most relevant to ras mutant positive tumors.

+ More Info


Pancreatic Cancer

Phase 1B of C3 in Adv Pancreatic and Solid Tumor Cancer

Mechanism:  Combination Metformin, Digoxin, Simvastatin (C3) knocks down BIRC5, a dominant cancer stimulatory protein.

+ More Info

Solid Tumor

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous eFT226 in Subjects with Selected Advanced Solid Tumor Malignancies

Mechanism:  eIF4E mRNA inhibitor

+ More Info

Phase 1B of C3 in Adv Pancreatic and Solid Tumor Cancer

Mechanism:  Combination Metformin, Digoxin, Simvastatin (C3) knocks down BIRC5, a dominant cancer stimulatory protein.

+ More Info

Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Advanced Solid Tumors

Mechanism:  Combination of non marrow suppressive signal pathway inhibition of PI3K with immune enhancing activity of checkpoint inhibitors to generate anticancer activity

+ More Info

Urothelial

Phase 3 study of Infigratinib phosphase or Placebo. For Invasive Urothelial Carcinoma w/ FGFR3

+ More Info



For more information about the clinical trials that are offered at the Eleanor N. Dana Cancer Center please contact Stephanie Smiddy at 419.383.6962
/
Last Updated: 7/7/20